In Vitro Susceptibility of Lefamulin Against Staphylococcus Aureus Isolated from Clinical Samples in a Tertiary Care Hospital

Riffat Bushra; Sakeenah Hussain Naqvi; Irfan Ali Mirza; Anam Imtiaz; Rabia Sajjad; Maria Mushtaq Gill

doi:10.51253/pafmj.v75i6.10503

Authors

Riffat Bushra Department of Microbiology, Armed Forces Institute of Pathology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Sakeenah Hussain Naqvi Department of Microbiology, Armed Forces Institute of Pathology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Irfan Ali Mirza Department of Microbiology, Armed Forces Institute of Pathology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Anam Imtiaz Department of Microbiology, Armed Forces Institute of Pathology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Rabia Sajjad Department of Microbiology, Armed Forces Institute of Pathology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Maria Mushtaq Gill Department of Microbiology, Armed Forces Institute of Pathology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v75i6.10503

Keywords:

Community-Acquired Bacterial Pneumonia (CABP), Lefamulin, Staphylococcus aureus

Abstract

Objective:To determine in vitro susceptibility of Lefamulin against Staphylococcus aureus isolated from respiratory samples in a tertiary care hospital in Pakistan.

Study Design: Cross sectional study.

Place and Duration of Study: Department of Microbiology Armed Forces Institute of Pathology, Rawalpindi, Pakistan from Jan to Jun 2022.

Methodology: The respiratory samples comprising of sputum, nasobronchial lavage (NBL), endobronchial washings (EBW) of patients were included in the study. The samples were processed at the Microbiology department laboratory using the standard microbiological procedures. The inoculation and incubation of specimens were done as per standard guidelines. The S. aureus isolates were identified on the basis of colony morphology, gram staining, Catalase, Coagulase and deoxyribonucleic acid-ase (DNAase) test.

Data was analysed using Statistical Package for Social Sciences (SPSS) 21.0. Frequencies and percentages were calculated for all quantitative variables.

Results: 215 specimens were evaluated, out of which 210(98.6%) were sensitive to Lefamulin. Out of these sensitive 212(98.6%) isolates 80(37.2%) belonged to EBW, 80(37.2%) from BAL, 40 (18.6%) from NBL and 15(7.0%) were sputum samples which were all sensitive.

Conclusion: This study showed that 98.6% of S. aureus were sensitive to Lefamulin antibiotic.

Downloads

Download data is not yet available.

References

1. Ghia CJ, Dhar R, Koul PA, Rambhad G, Fletcher MA. Streptococcus pneumoniae as a cause of community-acquired pneumonia in Indian adolescents and adults: a systematic review and meta-analysis. Clin Med Insights Circ Respir Pulm Med 2019; 13: 1179548419862790.

https://doi.org/10.1177/1179548419862790

2. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200(7): e45-67. https://doi.org/10.1164/rccm.201908-1581st

3. Peyrani P, Mandell L, Torres A, Tillotson GS. The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance. Expert Rev Respir Med 2019; 13(2): 139-152.

https://doi.org/10.1080/17476348.2019.1562339

4. Paukner S, Goldberg L, Alexander E, Das AF, Heinrich S, Patel P, et al. Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin. J Glob Antimicrob Resist 2022; 29: 434-443.

https://doi.org/10.1016/j.jgar.2021.10.021

5. Adhikary S, Duggal MK, Nagendran S, Chintamaneni M, Tuli HS, Kaur G. Lefamulin: A new hope in the field of community-acquired bacterial pneumonia. Cur Pharmacol Rep 2022; 8(6): 418-426. https://doi.org/10.1007/s40495-022-00297-6

6. Rhodes NJ, Jozefczyk CC, Moore WJ, Yarnold PR, Harkabuz K, Maxwell R et al. Characterizing risk factors for Clostridioides difficile infection among hospitalized patients with community-acquired pneumonia. Antimicrob Agents Chemother 2021; 65(7): 10-128. https://doi.org/10.1128/AAC.00417-21

7. Alexander E, Goldberg L, Das AF, Moran GJ, Sandrock C, Gasink LB, et al. Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial. JAMA 2019; 322(17): 1661-1671.

https://doi.org/10.1001/jama.2019.15468

8. File TM, Goldberg L, Das A, Sweeney C, Saviski J, Gelone SP, et al. Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial. Clin Infect Dis 2020; 70(11): 2459.

https://doi.org/10.1093/cid/ciz710

9. Chahine EB, Sucher AJ. Lefamulin: the first systemic pleuromutilin antibiotic. Ann Pharmacother 2020; 54(12): 1203-1214.

https://doi.org/10.3389/fvets.2025.1660872

10. Jacobsson S, Golparian D, Oxelbark J, Wicha WW, da Costa RM, Franceschi F, et al. Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating Neisseria gonorrhoeae infections. Front Pharmacol 2022; 13: 1035841.

https://doi.org/10.3389/fphar.2022.1035841

11. Shakeel S, Iffat W, Qamar A, Ghuman F, Yamin R, Ahmad N, et al. Pediatricians' Compliance to the Clinical Management Guidelines for Community-Acquired Pneumonia in Infants and Young Children in Pakistan. Healthcare 2021; 9(6): 701.

https://doi.org/10.3390/healthcare9060701

12. Sader HS, Paukner S, Gelone SP, Arends SR, Mendes RE. 1320. In Vitro Activity of Lefamulin against Staphylococcus aureus Isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis. Open Forum Infectious Dis 2021; 8(Supplement_1): S748-S749.

https://doi.org/10.1093/ofid/ofab466.1512

13. Leber AL. Clinical microbiology procedures handbook. John Wiley & Sons; 2020 Aug 6.

14. Humphries R, Bobenchik AM, Hindler JA, Schuetz AN. Overview of changes to the clinical and laboratory standards institute performance standards for antimicrobial susceptibility testing, M100. J Clin Microbiol 2021; 59(12): 10-128.

https://doi.org/10.1128/jcm.00213-21

15. Covvey JR, Guarascio AJ. Clinical use of lefamulin: A first‐in‐class semisynthetic pleuromutilin antibiotic. J Intern Med 2022; 291(1): 51-63. https://doi.org/10.1111/joim.13378

16. Paukner S, Mariano D, Das AF, Moran GJ, Sandrock C, Waites KB, et al. Lefamulin in patients with community-acquired bacterial pneumonia caused by atypical respiratory pathogens: pooled results from two phase 3 trials. Antibiotics 2021; 10(12): 1489. https://doi.org/10.3390/antibiotics10121489

17. Gilbert DN. The Sanford guide to antimicrobial therapy. BI Publications Pvt Ltd; 2006.

18. Kozhokar L, Levien TL, Baker DE. Lefamulin. Hosp Pharm 2022; 57(6): 704-711. https://doi.org/10.1177/0018578719897071

19. Dubey, A. P., Maggo, S., Karan, A., Singh, N. K., & Bhaskaran, S. (2019). Lefamulin: novel pleuromutilin drug for community acquired bacterial pneumonia. Int J Basic Clin Pharmacol 2019; 8(12): 2783–2790.

https://doi.org/10.18203/2319-2003.ijbcp20195297

20. Wu S, Zheng Y, Guo Y, Yin D, Zhu D, Hu F et al. In Vitro Activity of Lefamulin Against the Common Respiratory Pathogens Isolated From Mainland China During 2017–2019. Front Microbiol 2020; 16: 11:578824.

https://doi.org/10.3389/fmicb.2020.578824

21. Taylor RM, Karlowsky JA, Baxter MR, Adam HJ, Walkty A, Lagacé-Wiens P et al. In vitro susceptibility of common bacterial pathogens causing respiratory tract infections in Canada to lefamulin, a new pleuromutilin. J Assoc Med Microbiol Infect Dis Can 2021; 6(2): 149-162.

https://doi.org/10.3138/jammi-2020-0043